pmid	doi	year	title	Hugo_Symbol
23284223	10.1358/dof.2011.036.04.1588554	2022	Fostamatinib Disodium.	SYK
29721381	10.1080/2162402X.2017.1423183	2022	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.	SYK
32042774	10.21037/atm.2019.11.71	2022	Upregulated <i>miR-155</i> inhibits inflammatory response induced by <i>C. albicans</i> in human monocytes derived dendritic cells via targeting p65 and BCL-10.	SYK
32587490	10.4103/sjmms.sjmms_300_19	2022	Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.	SYK
34147695	10.1016/j.jmoldx.2021.04.013	2022	Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.	SYK
34193976	10.1038/s41375-021-01326-x	2022	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	SYK
34467417	10.1007/s00262-021-03043-x	2022	Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.	SYK
34890905	10.1016/j.neo.2021.12.001	2022	DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.	SYK
34993136	10.3389/fonc.2021.771669	2022	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.	SYK
35078814	10.1158/0008-5472.CAN-21-0218	2022	Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.	SYK
35197320	10.1124/jpet.121.000973	2022	ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets.	SYK
35205606	10.3390/cancers14040860	2022	Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.	SYK
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	SYK
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	SYK
35398488	10.1016/j.cellsig.2022.110331	2022	SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.	SYK
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	SYK
35597428	10.1016/j.cellsig.2022.110358	2022	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.	SYK
35605249	10.1182/bloodadvances.2022007695	2022	Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.	SYK
35681471	10.3390/cells11111777	2022	Pharmacological Inhibition of Spleen Tyrosine Kinase Suppressed Neuroinflammation and Cognitive Dysfunction in LPS-Induced Neurodegeneration Model.	SYK
23730399	10.6000/1927-7229.2012.01.01.1	2021	Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.	SYK
24851191	10.4236/jct.2014.51015	2021	SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.	SYK
31471373	10.3324/haematol.2019.216218	2021	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.	SYK
31831562	10.1158/1078-0432.CCR-19-2202	2021	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.	SYK
32090646	10.1080/10428194.2020.1713317	2021	Diffuse large B-cell lymphoma with low <sup>18</sup>F-fluorodeoxyglucose avidity features silent B-cell receptor signaling.	SYK
32327472	10.1158/1078-0432.CCR-19-3239	2021	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.	SYK
32341085	10.26508/lsa.202000700	2021	Immunoglobulin expression in the endoplasmic reticulum shapes the metabolic fitness of B lymphocytes.	SYK
32414848	10.3324/haematol.2019.241729	2021	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.	SYK
32688206	10.1016/j.ejca.2020.04.038	2021	Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.	SYK
32784334	10.1097/CM9.0000000000000999	2021	TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia.	SYK
33020271	10.1073/pnas.2007946117	2021	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	SYK
33089525	10.1111/ejh.13538	2021	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.	SYK
33259129	10.1111/jcmm.15851	2021	Prognostic and predictive value of a mRNA signature in peripheral T-cell lymphomas: A mRNA expression analysis.	SYK
33435587	10.3390/ijms22020592	2021	Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.	SYK
33615197	10.1016/j.isci.2021.102089	2021	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.	SYK
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	SYK
33670716	10.3390/biom11020308	2021	Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.	SYK
33777680	10.1016/j.apsb.2020.10.021	2021	A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.	SYK
33782605	10.1038/s41588-021-00803-4	2021	Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.	SYK
33878293	10.1016/j.molcel.2021.03.043	2021	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.	SYK
34043588	10.1172/JCI139675	2021	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming.	SYK
34177947	10.3389/fimmu.2021.689472	2021	Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	SYK
34204843	10.3390/cancers13122958	2021	Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma.	SYK
34323286	10.1002/eji.202048968	2021	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	SYK
34500771	10.3390/molecules26175340	2021	Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets.	SYK
30333224	10.1158/1078-0432.CCR-18-1047	2020	Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.	SYK
30609049	10.1002/jmv.25381	2020	Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-κB in B-cell lymphomas to increase MIP-1α production.	SYK
30633573	10.1080/10428194.2018.1562180	2020	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.	SYK
30663686	10.3791/58439	2020	Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.	SYK
30719267	10.1177/2040620718820510	2020	Novel treatment approaches and future perspectives in follicular lymphoma.	SYK
30819916	10.3324/haematol.2018.212811	2020	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.	SYK
30872780	10.1038/s41375-019-0442-8	2020	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	SYK
31030752	10.1016/bs.pmbts.2019.02.013	2020	Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China.	SYK
31040105	10.1158/2159-8290.CD-18-1393	2020	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.	SYK
31197205	10.1038/s41374-019-0262-5	2020	PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.	SYK
31362927	10.1182/bloodadvances.2018016162	2020	Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling.	SYK
31545408	10.3892/ijo.2019.4882	2020	Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.	SYK
31782972	10.1002/hon.2694	2020	New responsibilities for aged kinases in B-lymphomas.	SYK
31817853	10.3390/ijms20246175	2020	SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric <i>ETV6-RUNX1</i> B-Acute Lymphoblastic Leukemia Patients.	SYK
31943941	10.1002/art.41204	2020	Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.	SYK
32005797	10.1038/s41408-020-0277-6	2020	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	SYK
32481736	10.3390/cancers12061396	2020	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.	SYK
32620617	10.21873/anticanres.14367	2020	Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.	SYK
32702393	10.1016/j.exphem.2020.07.005	2020	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells.	SYK
25506060	10.1016/j.ebiom.2014.10.019	2019	A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATOR.	SYK
28460620	10.2174/1568009617666170427110450	2019	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.	SYK
29052597	10.1038/modpathol.2017.145	2019	SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma.	SYK
29246942	10.1158/1078-0432.CCR-17-2218	2019	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.	SYK
29340070	10.18632/oncotarget.22847	2019	A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.	SYK
29472356	10.3324/haematol.2017.184325	2019	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.	SYK
29572158	10.1016/j.clml.2018.02.017	2019	A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.	SYK
29642007	10.1016/j.celrep.2018.03.069	2019	How Biophysical Forces Regulate Human B Cell Lymphomas.	SYK
29740433	10.3389/fimmu.2018.00787	2019	SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production.	SYK
29881386	10.3389/fimmu.2018.01136	2019	Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.	SYK
29925955	10.1038/s41586-018-0290-0	2019	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	SYK
29934062	10.1016/j.clml.2018.05.022	2019	An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.	SYK
30183069	10.1111/bjh.15552	2019	An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.	SYK
30217447	10.1016/j.bbrc.2018.09.019	2019	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.	SYK
30402490	10.1155/2018/6728128	2019	Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.	SYK
30534553	10.1155/2018/1042597	2019	Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.	SYK
30592080	10.1002/ajh.25387	2019	Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.	SYK
30617194	10.1182/blood-2018-09-871418	2019	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.	SYK
30777096	10.1186/s13046-019-1076-4	2019	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.	SYK
27297662	10.1038/ncomms11889	2018	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.	SYK
27888629	10.18632/oncotarget.13557	2018	Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.	SYK
28639315	10.1111/his.13287	2018	MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.	SYK
28791394	10.3892/mmr.2017.7158	2018	Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.	SYK
28933554	10.1021/acs.molpharmaceut.7b00710	2018	Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.	SYK
29125235	10.1002/cam4.1257	2018	Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.	SYK
29279549	10.3960/jslrt.17019	2018	Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.	SYK
29781323	10.1080/14728214.2018.1479396	2018	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.	SYK
29855199	10.1080/13543784.2018.1482273	2018	Targeting the B cell receptor pathway in non-Hodgkin lymphoma.	SYK
30066853	10.3892/ijo.2018.4513	2018	Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.	SYK
30135222	10.1128/mSphereDirect.00378-18	2018	Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.	SYK
26354285	10.1002/hon.2251	2017	Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.	SYK
26847027	10.1038/leu.2016.9	2017	Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.	SYK
26968534	10.1182/blood-2015-12-683516	2017	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.	SYK
27264434	10.1111/cbdd.12798	2017	3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.	SYK
27297792	10.1182/blood-2016-03-707141	2017	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.	SYK
27406873	10.1002/jcph.794	2017	PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.	SYK
27432944	10.1084/jem.20151932	2017	E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity.	SYK
27476075	10.1159/000446879	2017	Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease.	SYK
27641927	10.1016/j.phrs.2016.09.011	2017	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.	SYK
27720936	10.1016/j.exphem.2016.09.011	2017	MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.	SYK
27758892	10.1158/0008-5472.CAN-16-1899	2017	E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.	SYK
27839918	10.1016/j.bmcl.2016.10.087	2017	Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).	SYK
27899526	10.1126/scisignal.aaf3949	2017	Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia.	SYK
28011673	10.1182/blood-2016-05-718494	2017	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.	SYK
28064214	10.1182/blood-2016-06-721423	2017	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.	SYK
28088788	10.18632/oncotarget.14588	2017	Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.	SYK
28147336	10.18632/oncotarget.14876	2017	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.	SYK
28291124	10.1097/PAS.0000000000000799	2017	MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.	SYK
28359287	10.1186/s13045-017-0447-6	2017	Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.	SYK
28368423	10.1038/onc.2017.95	2017	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.	SYK
28462919	10.1038/leu.2017.129	2017	Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.	SYK
28646116	10.1182/blood-2016-10-747303	2017	Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.	SYK
25682964	10.3109/10428194.2015.1017820	2016	The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia.	SYK
25748087	10.1158/1078-0432.CCR-14-1462	2016	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.	SYK
26184912	10.1038/cdd.2015.97	2016	BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma.	SYK
26194765	10.1182/blood-2015-04-640805	2016	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.	SYK
26285772	10.1016/j.ebiom.2015.04.005	2016	Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.	SYK
26288809	10.1016/j.ebiom.2015.05.001	2016	Nanoparticle Formulation to Improve the Efficacy of Radiation Therapy Against Radiation-resistant Leukemia.	SYK
26406451	10.1016/j.biomaterials.2015.09.007	2016	Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.	SYK
26529251	10.1172/JCI80714	2016	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.	SYK
26575169	10.18632/oncotarget.6316	2016	Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.	SYK
26585955	10.1182/blood-2015-06-654111	2016	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.	SYK
26621451	10.1084/jem.20151074	2016	Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.	SYK
26637705	10.1182/asheducation-2015.1.82	2016	B-cell receptor pathway modulators in NHL.	SYK
26639163	10.1038/srep17868	2016	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.	SYK
26707592	10.1016/j.ejca.2015.10.005	2016	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).	SYK
26785729	10.1074/mcp.M115.054593	2016	High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells.	SYK
24547708	10.3109/10428194.2014.891026	2015	Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.	SYK
24806599	10.1038/ncomms4755	2015	An ITAM-Syk-CARD9 signalling axis triggers contact hypersensitivity by stimulating IL-1 production in dendritic cells.	SYK
24910947	10.1039/c4ib00095a	2015	CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.	SYK
24948121	10.1038/nrd4371	2015	Anticancer drugs: Hitting SYK in B-ALL leukaemia.	SYK
25080849	10.1111/ejh.12427	2015	B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.	SYK
25148222	10.1038/bcj.2014.53	2015	Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.	SYK
25222877	10.1016/j.ejmech.2014.09.018	2015	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.	SYK
25252690	10.1158/2159-8290.CD-14-0096	2015	Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.	SYK
25253883	10.1124/jpet.114.218164	2015	The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.	SYK
25337257		2015	Angioimmunoblastic T-cell lymphoma in Taiwan shows a frequent gain of ITK gene.	SYK
25381061	10.1182/blood-2014-04-571331	2015	HGAL localization to cell membrane regulates B-cell receptor signaling.	SYK
25388373	10.1002/ijc.29326	2015	Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.	SYK
25484043	10.4161/19420862.2014.979081	2015	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.	SYK
25604350	10.1007/s00428-015-1716-9	2015	Follicular variant of peripheral T cell lymphoma with mediastinal involvement in a child: a case report.	SYK
25631773	10.1182/blood-2014-08-594689	2015	Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1.	SYK
25696919	10.1182/blood-2014-08-595934	2015	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.	SYK
25759025	10.1016/j.ccell.2015.02.003	2015	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.	SYK
25799995	10.1038/nature14231	2015	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.	SYK
26251761	10.1186/s40164-015-0016-z	2015	Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.	SYK
26675306	10.1016/j.bbacli.2014.06.003	2015	Molecular profiling of childhood cancer: Biomarkers and novel therapies.	SYK
23535559	10.1038/leu.2013.89	2014	SYK regulates mTOR signaling in AML.	SYK
23597135	10.3109/10428194.2013.796055	2014	MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia.	SYK
23886341	10.3109/08830185.2013.818141	2014	B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.	SYK
23886342	10.3109/08830185.2013.818140	2014	B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.	SYK
23886693	10.1016/j.imbio.2013.06.013	2014	Activation of NF-κB and respiratory burst following Aspergillus fumigatus stimulation of macrophages.	SYK
23917087	10.1016/j.ejmech.2013.04.070	2014	Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.	SYK
24018164	10.1016/j.semcancer.2013.08.011	2014	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.	SYK
24169826	10.1182/blood-2012-12-473090	2014	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	SYK
24376268	10.4049/jimmunol.1300420	2014	Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk.	SYK
24828076	10.1126/scitranslmed.3008661	2014	Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.	SYK
25092868	10.1128/MCB.00937-14	2014	Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.	SYK
22409820	10.1016/j.beha.2012.01.004	2013	New biomarkers in T-cell lymphomas.	SYK
22616724	10.3109/10428194.2012.695781	2013	Targeting the B cell receptor pathway in chronic lymphocytic leukemia.	SYK
22845486	10.2165/11594740-000000000-00000	2013	Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.	SYK
22865093	10.1007/s11912-012-0254-8	2013	B-cell receptor pathobiology and targeting in NHL.	SYK
22880054	10.1371/journal.pone.0042610	2013	Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.	SYK
22966017	10.1158/1078-0432.CCR-12-0397	2013	Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.	SYK
23039362	10.3109/10428194.2012.736983	2013	Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.	SYK
23071339	10.1073/pnas.1209828109	2013	Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros.	SYK
23072591	10.1186/1471-2407-12-478	2013	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.	SYK
23220742	10.1124/jpet.112.200832	2013	The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.	SYK
23231952	10.1158/1078-0432.CCR-12-1935	2013	Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.	SYK
23270582	10.3109/10428194.2012.754097	2013	B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn.	SYK
23293025	10.1074/jbc.M112.374967	2013	Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70.	SYK
23299888	10.1038/ncomms2334	2013	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.	SYK
23396081	10.1016/j.pharmthera.2013.02.001	2013	Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.	SYK
23398911	10.1111/ajt.12137	2013	Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.	SYK
23523010	10.1016/j.it.2013.02.006	2013	Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation.	SYK
23568490	10.1182/blood-2012-11-470633	2013	Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.	SYK
23603515	10.1016/j.exphem.2013.04.006	2013	Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels.	SYK
23604103	10.1007/s00262-013-1403-0	2013	Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.	SYK
23764004	10.1016/j.ccr.2013.05.002	2013	SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.	SYK
23883968	10.1038/nri3487	2013	New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.	SYK
23933705	10.1038/bcj.2013.32	2013	Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.	SYK
24076779	10.1097/PAS.0b013e3182991415	2013	ITK/SYK translocation in angioimmunoblastic T-cell lymphoma.	SYK
21518255	10.1111/j.1742-4658.2011.08134.x	2012	TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.	SYK
21749309	10.3109/10428194.2011.594926	2012	Heterogeneous expression of Src tyrosine kinases Lyn, Fyn and Syk in classical Hodgkin lymphoma: prognostic implications.	SYK
21926965	10.1038/leu.2011.248	2012	Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis.	SYK
22025527	10.1182/blood-2011-02-333773	2012	SYK inhibition and response prediction in diffuse large B-cell lymphoma.	SYK
22108298	10.1016/j.mrrev.2011.11.001	2012	Biological activity of piceatannol: leaving the shadow of resveratrol.	SYK
22110251	10.1182/blood-2011-02-339556	2012	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets.	SYK
22262777	10.1182/blood-2011-04-351965	2012	CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells.	SYK
22301676	10.1038/leu.2012.10	2012	Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.	SYK
22353174	10.1111/j.1399-3046.2012.01656.x	2012	Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.	SYK
22373549	10.1007/s00277-012-1431-4	2012	Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia.	SYK
22510872	10.1182/blood-2011-12-396150	2012	Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.	SYK
22609829	10.1016/j.antiviral.2012.05.003	2012	Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.	SYK
22612424	10.1517/13543784.2012.685650	2012	Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.	SYK
22688757	10.1007/s11899-012-0127-0	2012	The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.	SYK
22700864	10.1158/1078-0432.CCR-11-3152	2012	New strategies in the treatment of mantle cell lymphoma.	SYK
22915648	10.1182/blood-2012-02-413252	2012	Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.	SYK
20511667	10.3324/haematol.2009.021428	2011	Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.	SYK
20736517	10.1292/jvms.10-0225	2011	Analysis of Syk expression in bovine lymphoma and persistent lymphocytosis induced by bovine leukemia virus.	SYK
20836676	10.1586/era.10.112	2011	Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.	SYK
20875408	10.1016/j.yexcr.2010.09.011	2011	Membrane-associated signaling in human B-lymphoma lines.	SYK
21127342	10.1258/ebm.2010.010056	2011	Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.	SYK
21148756	10.1158/1055-9965.EPI-10-0638	2011	Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma.	SYK
21239804	10.1182/asheducation-2010.1.265	2011	Signal transduction inhibitor therapy for lymphoma.	SYK
21281601	10.1016/j.bbrc.2011.01.088	2011	GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.	SYK
21364752	10.1371/journal.pone.0016596	2011	Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines.	SYK
21394647	10.1007/s13402-011-0019-7	2011	Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling.	SYK
21416481	10.1002/hon.981	2011	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.	SYK
21429356		2011	[Follicular variant of peripheral T-cell lymphoma: a clinicopathologic and genetic study of 2 cases].	SYK
21438742	10.1517/13543784.2011.570329	2011	The Syk kinase as a therapeutic target in leukemia and lymphoma.	SYK
21438839	10.3109/10428194.2011.568649	2011	The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.	SYK
21658626	10.1016/j.beha.2011.03.006	2011	New agents in follicular lymphoma.	SYK
21865343	10.1182/blood-2011-01-333682	2011	ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.	SYK
21908615	10.1074/jbc.M111.255125	2011	Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.	SYK
19776763	10.1038/leu.2009.198	2010	Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.	SYK
19855081	10.1182/blood-2009-02-204362	2010	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.	SYK
19912216	10.1111/j.1365-2141.2009.07983.x	2010	Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.	SYK
19965662	10.1182/blood-2009-08-236471	2010	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.	SYK
19965664	10.1182/blood-2009-08-237537	2010	Rituximab inhibits B-cell receptor signaling.	SYK
20043832	10.1186/1476-4598-8-132	2010	Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.	SYK
20133729	10.1073/pnas.0909086107	2010	STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.	SYK
20151979	10.1111/j.1365-2141.2010.08106.x	2010	Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.	SYK
20378171	10.1016/j.leukres.2010.03.026	2010	Syk expression patterns differ among B-cell lymphomas.	SYK
20439538	10.1084/jem.20100608	2010	Peripheral T cell lymphoma: new model + new insight.	SYK
20439541	10.1084/jem.20092042	2010	The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.	SYK
20538615	10.1074/jbc.M110.131300	2010	CARD9 mediates dectin-2-induced IkappaBalpha kinase ubiquitination leading to activation of NF-kappaB in response to stimulation by the hyphal form of Candida albicans.	SYK
20559762	10.1007/s12185-010-0609-6	2010	Targeted treatment and new agents in diffuse large B cell lymphoma.	SYK
20654581	10.1016/j.bcp.2010.07.017	2010	The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.	SYK
20670954	10.1158/0008-5472.CAN-08-3719	2010	The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease.	SYK
18981293	10.1182/blood-2008-05-158618	2009	Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.	SYK
19007249	10.1021/ac801940w	2009	Total internal reflection fluorescence flow cytometry.	SYK
19092849	10.1038/leu.2008.346	2009	Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.	SYK
19131553	10.1182/blood-2008-08-175901	2009	Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.	SYK
19136564	10.1074/jbc.M806650200	2009	Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells.	SYK
19139169	10.1084/jem.20081445	2009	Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation.	SYK
19150402	10.1016/j.cellsig.2008.12.006	2009	SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux.	SYK
19295409	10.1097/PAS.0b013e3181971591	2009	Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.	SYK
19296913	10.1016/j.cellsig.2009.03.007	2009	Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation.	SYK
19333898		2009	Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.	SYK
19369227	10.1182/blood-2009-02-206128	2009	Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.	SYK
19428562	10.1016/j.imlet.2009.03.005	2009	Barley-derived beta-D-glucan induces immunostimulation via a dectin-1-mediated pathway.	SYK
19535334	10.1074/jbc.M109.034272	2009	The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation.	SYK
19608873	10.2353/ajpath.2009.080451	2009	Activation of mTORC1 signaling pathway in AIDS-related lymphomas.	SYK
19850008	10.1016/j.bbrc.2009.10.070	2009	Phosphatidylinositol-3-kinase-dependent phosphorylation of SLP-76 by the lymphoma-associated ITK-SYK fusion-protein.	SYK
19892728	10.1182/blood-2009-08-239988	2009	Integrity of the CBL gene in mature B-cell malignancies.	SYK
18006696	10.1182/blood-2007-07-100115	2008	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.	SYK
18401419	10.1038/leu.2008.77	2008	Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.	SYK
18426802	10.1074/jbc.M708459200	2008	Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.	SYK
18430472	10.1016/j.molimm.2008.03.002	2008	EBV transformation overrides gene expression patterns of B cell differentiation stages.	SYK
18434405	10.1128/JVI.02637-07	2008	Critical role for endocytosis in the regulation of signaling by the Kaposi's sarcoma-associated herpesvirus K1 protein.	SYK
18596745	10.1038/leu.2008.163	2008	Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.	SYK
18760704	10.1053/j.seminhematol.2008.07.004	2008	Targeted treatment and new agents in diffuse large B-cell lymphoma.	SYK
18954749	10.1016/j.hoc.2008.07.006	2008	New drugs for the treatment of lymphoma.	SYK
16888096	10.1182/blood-2006-03-013821	2007	Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.	SYK
16912221	10.1182/blood-2006-05-026203	2007	Syk-dependent mTOR activation in follicular lymphoma cells.	SYK
17038529	10.1182/blood-2006-03-011759	2007	ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.	SYK
17182546	10.4049/jimmunol.178.1.111	2007	Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.	SYK
17489982	10.1111/j.1365-2141.2007.06597.x	2007	Studies of a germinal centre B-cell expressed gene, GCET2, suggest its role as a membrane associated adapter protein.	SYK
17717600	10.1172/JCI30842	2007	B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.	SYK
15996927		2006	ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.	SYK
16160011	10.1182/blood-2005-06-2273	2006	Transmembrane adaptor molecules: a new category of lymphoid-cell markers.	SYK
16160012	10.1182/blood-2005-04-1755	2006	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.	SYK
16289966	10.1016/j.cellsig.2005.10.001	2006	Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav.	SYK
16304050	10.1182/blood-2005-09-3765	2006	Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.	SYK
16307012	10.1038/sj.leu.2404046	2006	Peripheral T-cell non-Hodgkin's lymphoma NOS: naming of parts.	SYK
16341044	10.1038/sj.leu.2404045	2006	Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma.	SYK
16409295	10.1111/j.1365-2141.2005.05883.x	2006	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.	SYK
16670274	10.4049/jimmunol.176.10.5715	2006	Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma.	SYK
16835385	10.1182/blood-2006-02-003921	2006	Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells.	SYK
16849475	10.4049/jimmunol.177.3.1661	2006	Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.	SYK
16862125	10.1038/nature04926	2006	Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.	SYK
15345594	10.1182/blood-2003-08-2965	2005	The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor.	SYK
15580314	10.1038/sj.onc.1208032	2005	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors.	SYK
15744341	10.1038/sj.leu.2403702	2005	Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma.	SYK
15812353		2005	The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines.	SYK
15914563	10.1182/blood-2004-10-3898	2005	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.	SYK
15939795	10.1084/jem.20042101	2005	Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.	SYK
15948116	10.1016/j.humpath.2005.03.004	2005	Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.	SYK
16192589	10.1200/JCO.2005.01.4944	2005	Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis.	SYK
12881301	10.1182/blood-2003-05-1487	2004	Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease.	SYK
14747535	10.1128/jvi.78.4.1697-1705.2004	2004	Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway.	SYK
14984504	10.1111/j.1365-2141.2004.04802.x	2004	Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples.	SYK
15032688	10.2174/1381612043452947	2004	B cell responses to oxidative stress.	SYK
15132768	10.1111/j.1349-7006.2004.tb03224.x	2004	Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo.	SYK
12400606	10.1080/1042819021000002965	2003	Genomic studies of the spleen protein tyrosine kinase locus reveal a complex promoter structure and several genetic variants.	SYK
12400610	10.1080/1042819021000003009	2003	The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.	SYK
12470302	10.1186/1471-2172-3-16	2003	Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.	SYK
12533043	10.1080/1042819021000032935	2003	SYK and LYN mediate B-cell receptor-independent calcium-induced apoptosis in DT-40 lymphoma B-cells.	SYK
12542476	10.1046/j.1365-2141.2003.04044.x	2003	Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia.	SYK
12717427	10.1038/sj.onc.1206313	2003	Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia.	SYK
11698646	10.1073/pnas.231486598	2002	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.	SYK
11714793	10.4049/jimmunol.167.11.6292	2002	The IL-15R alpha chain signals through association with Syk in human B cells.	SYK
11731410		2002	Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.	SYK
11970976	10.4049/jimmunol.168.9.4344	2002	Transmodulation of BCR signaling by transduction-incompetent antigen receptors: implications for impaired signaling in anergic B cells.	SYK
12072546	10.1093/jnci/94.12.926	2002	Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene.	SYK
12094251	10.1038/sj.leu.2402523	2002	Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells.	SYK
12148895	10.1080/10428190290021650	2002	A dual function anti-leukemic agent with anti-thrombotic activity.	SYK
12188892	10.2174/1568009013334287	2002	Structure-based design of novel anticancer agents.	SYK
11063874	10.1016/s0301-472x(00)00538-5	2001	Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells.	SYK
11187083	10.1007/978-3-642-57284-5_16	2001	Life and death decisions in B1 lymphoma cells.	SYK
11390590	10.1128/JVI.75.13.5891-5898.2001	2001	Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication.	SYK
11489945	10.1084/jem.194.3.255	2001	Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.	SYK
11494125	10.1038/sj.onc.1204515	2001	Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.	SYK
11591765	10.4049/jimmunol.167.8.4405	2001	CXCR3 expression on CD34(+) hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor: II. Signaling pathways involved.	SYK
10617633	10.1074/jbc.275.1.414	2000	The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase.	SYK
10747947	10.1074/jbc.M000689200	2000	Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk.	SYK
10903730	10.4049/jimmunol.165.3.1300	2000	B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.	SYK
11044134	10.1128/jvi.74.22.10838-10845.2000	2000	Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.	SYK
10072516		1999	Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation.	SYK
10196263	10.1128/JVI.73.5.3709-3717.1999	1999	Altered expression of tyrosine kinases of the Src and Syk families in human T-cell leukemia virus type 1-infected T-cell lines.	SYK
10359809	10.1073/pnas.96.12.6890	1999	The tyrosine kinases Syk and Lyn exert opposing effects on the activation of protein kinase Akt/PKB in B lymphocytes.	SYK
10498607		1999	Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.	SYK
9796924	10.1093/intimm/10.10.1573	1999	p72syk protein tyrosine kinase: an early transducer of sIgG-triggered apoptotic signalling in human follicular lymphoma cells.	SYK
9865907		1999	Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells.	SYK
9461594	10.1074/jbc.273.7.4035	1998	Stimulation of Src family protein-tyrosine kinases as a proximal and mandatory step for SYK kinase-dependent phospholipase Cgamma2 activation in lymphoma B cells exposed to low energy electromagnetic fields.	SYK
9464522	10.1016/s0161-5890(97)00111-9	1998	Activation of syk in an immature B cell line does not require lyn activity.	SYK
9531288		1998	Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction.	SYK
9565626	10.1074/jbc.273.19.11970	1998	Major histocompatibility class II-mediated signal transduction is regulated by the protein-tyrosine phosphatase CD45.	SYK
9570929	10.1006/excr.1998.4014	1998	Protein tyrosine kinases p53/56lyn and p72syk in MHC class I-mediated signal transduction in B lymphoma cells.	SYK
9613615	10.1016/s0014-5793(98)00383-4	1998	A deficiency in Syk enhances ceramide-induced apoptosis in DT40 lymphoma B cells.	SYK
9651374	10.1074/jbc.273.28.17742	1998	Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells.	SYK
9730884	10.1084/jem.188.5.819	1998	Syk tyrosine kinase and B cell antigen receptor (BCR) immunoglobulin-alpha subunit determine BCR-mediated major histocompatibility complex class II-restricted antigen presentation.	SYK
8993005		1997	Association of non-receptor protein tyrosine kinases with the Fc gamma RI/gamma-chain complex in monocytic cells.	SYK
9049959	10.3109/10428199609045711	1997	Antigen receptor function in chronic lymphocytic leukemia B cells.	SYK
9052872	10.1016/s0165-2478(96)02667-3	1997	Membrane-bound ezrin is involved in B-cell receptor-mediated signaling: potential role of an ITAM-like ezrin motif.	SYK
9192767		1997	Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established.	SYK
9200459		1997	B cell antigen receptor desensitization: disruption of receptor coupling to tyrosine kinase activation.	SYK
9202044	10.1074/jbc.272.27.17209	1997	Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling.	SYK
9233602		1997	Cross-linking of the IgM receptor induces rapid translocation of IgM-associated Ig alpha, Lyn, and Syk tyrosine kinases to the membrane skeleton.	SYK
9264390	10.1038/sj.leu.2400745	1997	Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk.	SYK
8688094	10.1126/science.273.5278.1096	1996	BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells.	SYK
8756661	10.1128/MCB.16.9.5026	1996	Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function.	SYK
8892612		1996	A novel complex, p40/42, is constitutively associated with the B cell antigen receptor and phosphorylated upon receptor stimulation.	SYK
7541023	10.1016/0165-2478(94)00207-8	1995	Rapid desensitization of B-cell receptor by a dithiol-reactive protein tyrosine phosphatase inhibitor: uncoupling of membrane IgM from syk inhibits signals leading to Ca2+ mobilization.	SYK
7657667	10.1074/jbc.270.35.20824	1995	Lineage-specific induction of B cell apoptosis and altered signal transduction by the phosphotyrosine phosphatase inhibitor bis(maltolato)oxovanadium(IV).	SYK
7512564		1994	Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel.	SYK
7515102	10.1084/jem.179.6.1923	1994	CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein.	SYK
7519980	10.1002/elps.1150150161	1994	Purification and identification of tyrosine-phosphorylated proteins from B lymphocytes stimulated through the antigen receptor.	SYK
1372019		1992	Membrane Ig cross-linking regulates phosphatidylinositol 3-kinase in B lymphocytes.	SYK
